Skip to main content

BioAtla, Inc.

BCAB
Exchange
OTC
Industry
Biological Products, (No Diagnostic Substances)
SEC CIK
0001826892

No open-market purchases or sales by BioAtla, Inc. insiders were filed in the last 90 days; 21 institutions reported holding it in 13F filings for Q2 2026, worth $1.22M in total; no superinvestor holds it.

Q4 2023 vs. Q3 2023

How the institutions holding BioAtla, Inc. changed between Q3 2023 and Q4 2023.

All holders in Q4 2023All holders in Q3 2023

13F holders of BCAB: Q3 2023 compared with Q4 2023
MeasureQ3 2023Q4 2023Change
Holders8279−3
Shares30.1M27.0M−3.11M (−10.3%)
Value$51.3M$66.6M+$15.2M (+29.7%)

New holders (14)

Institutions that held BioAtla, Inc. at the end of Q4 2023 but not at the end of Q3 2023.

Institutions new to BCAB in Q4 2023
InstitutionSharesValue% of portfolio
Jane Street Group, LLC116,999$287.8K0.00%
Acadian Asset Management LLC98,440$241.0K0.00%
Perceptive Advisors LLC73,000$179.6K0.00%
PVG Asset Management Corp65,335$160.7K0.78%
Marshall Wace, LLP45,383$111.6K0.00%
Rinkey Investments25,310$62.3K0.02%
Engineers Gate Manager LP20,031$49.3K0.00%
Susquehanna Portfolio Strategies, LLC18,691$46.0K0.00%
Envestnet Asset Management Inc17,978$44.2K0.00%
Advisor Group Holdings, Inc.16,894$41.6K0.00%
Wexford Capital LP11,830$29.1K0.01%
State Board of Administration of Florida Retirement System11,486$28.3K0.00%
EverSource Wealth Advisors, LLC237$5830.00%
The PNC Financial Services Group, Inc.73$1800.00%

Sold out (17)

Institutions that held BioAtla, Inc. at the end of Q3 2023 and filed for Q4 2023 without it.